Mounjaro KwikPen 2.5mg: the starter dose explained

Why the 2.5mg KwikPen is the starting point, not the endpoint

When a prescriber puts you on Mounjaro, the first pen you receive will always be the 2.5mg strength. That holds true whether your BMI is 30 or 45, whether you have one weight-related condition or several. The reason is physiological, not cautious paperwork: tirzepatide activates two gut-hormone receptors (GIP and GLP-1) and that dual action can cause nausea, bloating or loose stools in the early weeks, especially if the dose climbs too fast. Beginning at 2.5mg means most of those effects stay mild and pass within days rather than becoming a reason to stop.

Think of it this way: the first pen's job is adjustment. Weight loss follows later, at higher doses where the appetite-suppressing effect becomes clinically meaningful. Clinical trials reported average weight reductions of around 20–21% at the 15mg maintenance dose over 72 weeks, but that outcome is built on a titration schedule that starts exactly here, at 2.5mg. The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and documented results across the full dose journey, not from week one alone.

One practical habit worth building early: before you inject each week, check the liquid in the pen window. It should be clear and colourless. If it looks cloudy or contains particles, do not use it, contact your prescriber or pharmacy. That takes less than a minute and is the single most useful pre-injection check you can do. For a full walkthrough of the injection steps, our guide to using the Mounjaro KwikPen covers the process in detail.

The titration decision: who moves up and when

After four weeks at 2.5mg, your prescriber will review your response. The licensed schedule progresses in 2.5mg steps (to 5mg, then 7.5mg, and so on up to 15mg) with each dose held for at least four weeks before any increase is considered. That pacing is not arbitrary. It mirrors the approach tested across the SURMOUNT trial programme and reflects the guidance in the NHS's patient information on tirzepatide.

Whether to move up depends on tolerability and clinical response, not on impatience. Some people sail through 2.5mg with minimal side effects and are ready to progress quickly. Others need longer at the starter dose, particularly if nausea is lingering. The prescriber, not the patient, makes that call. This is why clinical re-review before every repeat matters: a prescriber looking at your actual progress can judge whether a dose increase is appropriate, rather than applying a fixed calendar.

It is also worth knowing that Mounjaro's licensed strengths run from 2.5mg up to 15mg. If you are curious about what the next step involves, the 5mg KwikPen page explains what changes at that stage. For those further along the schedule, there is also detail on the 7.5mg dose. Each increase is a clinical decision, not a given.

For context on how the maintenance phase eventually works once you reach your highest tolerated dose, our page on Mounjaro maintenance dosing explains the longer-term picture.

Side effects at 2.5mg and what they mean for the weeks ahead

The most common side effects of tirzepatide are gastrointestinal: nausea, constipation, diarrhoea, indigestion, and occasionally vomiting. At 2.5mg, most people find these are at their mildest, which is precisely the point. They tend to peak in the first few days after an injection and ease before the next one is due.

Fatigue and headache are less common but do occur, usually in the first week or two. Injection-site reactions (mild redness or itching where you injected) are normal and typically short-lived. Rotating your injection site each week (between abdomen, thigh and upper arm) helps keep reactions to a minimum.

A small number of people experience more persistent nausea or stomach discomfort that does not settle. That is important to report to your prescriber rather than wait out alone: it may affect the titration timeline or signal that a different approach is needed. Separately, anyone who develops severe, persistent stomach pain that spreads toward the back should seek urgent medical attention, this can be a sign of acute pancreatitis, which the MHRA highlighted as a known but infrequent serious risk in its January 2026 Drug Safety Update on GLP-1 medicines.

Questions about how side effects compare between doses, or what the broader treatment journey looks like, are well-suited to a consultation. Our Mounjaro overview page pulls together the wider clinical picture, and if you are weighing up what getting started actually involves, our page on accessing Mounjaro through a regulated online pharmacy explains the process clearly.

Where the 2.5mg KwikPen fits in the cost picture

The 2.5mg pen is available for four weeks of treatment, just like every other strength in the range. Private prices for Mounjaro vary by dose and provider. After Eli Lilly raised UK list prices from September 2025, reported private market prices across providers have ranged roughly £149–£375 per month by dose, with the starter doses typically at the lower end of that range. Those figures are widely reported estimates; the actual price you pay depends on the provider and what is included.

At nume, one transparent price covers the consultation, prescription, the treatment itself and free next-working-day delivery, no subscription, no auto-renewal, and a named prescriber reviews every order before it is dispensed. If you want to understand what the full cost of treatment involves, the treatment page sets out current pricing clearly.

The 2.5mg starting dose is often the lowest-cost entry point to tirzepatide, but it is still a prescription medicine requiring clinical assessment. That step is not a formality. Exploring weight-loss treatment options alongside that assessment gives you the clearest picture of whether Mounjaro is the right fit. When you are ready, check your eligibility through a free consultation with our prescribers.